Using Whole-Genome Analysis on Cancer Tissue of Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
Latest Information Update: 05 Apr 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Apr 2019 New trial record